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Tumor necrosis factor (TNF) plays a pathogenic role in psoriasis and rheumatoid arthritis but is essential for host
defenses against mycobacteria and other granulomatous pathogens. The risk of reactivation of latent
Mycobacterium tuberculosis infection is significantly greater with the TNF monoclonal antibody infliximab
than with the soluble TNF-receptor etanercept. We have examined the biologic basis of this difference using
whole blood culture. Infliximab and adalimumab reduced the proportion of T buciclate-responsive cells by 70
and 50%, respectively, and suppressed antigen-induced IFN-g production by 70 and 64%. In contrast, etanercept
produced no significant effect. The difference between infliximab and etanercept remained whether one
compared equal or peak therapeutic drug concentrations, suggesting a relationship to mechanism of action
rather than pharmacokinetics. Adalimumab and etanercept caused divergent, concentration dependent effects
on control of intracellular growth of M. tuberculosis. None of the drugs induced significant levels of apoptosis
or necrosis in monocytes or T cells, excluding T-cell death as a mechanism for suppression of antigen-induced
responses. IL-10 production was equally suppressed by all three drugs, excluding excess IL-10 as a regulatory
mechanism. The tuberculosis risk posed by infliximab may reflect its combined effects on TNF and IFNg.
Journal of Investigative Dermatology Symposium Proceedings (2007) 12, 16–21. doi:10.1038/sj.jidsymp.5650031
INTRODUCTION
Tumor necrosis factor (TNF) drives the cytokine cascade at
sites of inflammation (Brennan et al., 1989). Produced by
lymphocytes and macrophages first as a transmembrane
protein, TNF is then cleaved to form the mature soluble
cytokine. Biologic activity is conferred by aggregation to form
trimeric TNF (Eck and Sprang, 1989). TNF acts by binding to
two types of receptors, p55 (high affinity) and p75 (low
affinity), the trimeric structures of which mimic that of the
active cytokine. The two receptors exert both shared and
unique activities, stimulating the release of inflammatory
cytokines, endothelial adhesion molecules, and chemokines,
and coordinating the migration of leukocytes to targeted
organs (Roach et al., 2002).
TNF is essential for host defenses against Mycobacterium
tuberculosis and other pathogens not readily killed by other
host defense mechanisms. Instead, these organisms are
sequestered within granulomas comprised of a central core
of multinucleated giant cells and necrotic debris, surrounded
by epithelioid macrophages and lymphocytes (Randhawa,
1990). TNF is required for the orderly recruitment of these
cells and for the continued maintenance of granuloma
structure. Animals lacking the gene for TNF, treated with
neutralizing anti-TNF antibody, or genetically engineered to
overexpress soluble TNF receptor show increased suscepti-
bility to M. tuberculosis, Listeria monocytogenes, and
Histoplasma capsulatum, as well as to attenuated organisms
such as M. bovis BCG, in both acute and chronic infection
models (Kindler et al., 1989; Garcia et al., 1995, 1997;
Allendoerfer and Deepe, 1998; Peschon et al., 1998; Kaneko
et al., 1999; Bopst et al., 2001).
Recognition of the central role of TNF in the pathogenesis
of chronic inflammation has profoundly changed the treat-
ment of diseases such as rheumatoid arthritis, and psoriasis,
with the introduction into clinical use of infliximab in 1998,
etanercept in 1999, and adalimumab in 2004. Nearly one-
million patients have been treated worldwide with infliximab
or etanercept; approximately 20,000 have been treated to
date with adalimumab (Schiff et al., 2006). These agents
appear to be similarly highly effective for conditions such as
rheumatoid arthritis for which all are indicated. This review
will examine epidemiologic and immunologic data regarding
the differential effects of these treatments on risk of
granulomatous infection and underlying modulation of the
human cellular immune response.
TNF BLOCKADE AND GRANULOMATOUS INFECTIONS:
AERS DATA
Human tuberculosis may arise due to progression of new
infection or reactivation of latent infection. Reactivation is
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not readily modeled in experimental animals, except as
exacerbation of chronic disease. Nonetheless, the experi-
mental data indicate that TNF lack might increase disease risk
through effects on both pathogenic mechanisms. Indeed,
accumulating evidence indicates several granulomatous
infections, including tuberculosis, histoplasmosis, cryptococ-
cosis, coccidioidomycosis, listeriosis, and aspergillosis, occur
with increased frequency in patients treated with TNF
blockers (Keane et al., 2001; Warris et al., 2001; Lee et al.,
2002; True et al., 2002; Slifman et al., 2003). These risks do
not appear to be equally represented across the class, but
instead, are greater with infliximab compared to etanercept
(Lee et al., 2002; Bergstrom et al., 2004; Wallis et al., 2005).
The largest and most systematic study of this question,
performed using the US Food and Drug Administration
Adverse Event Reporting System, found that T buciclate (TB),
histoplasmosis, and other granulomatous infections occurred
more often, more rapidly, and with greater risk of dissemina-
tion with infliximab than etanercept (Wallis et al., 2005). The
crude risk ratios for these diseases (infliximab:etanercept)
ranged from approximately 2 to 10. The distribution of
tuberculosis cases in relation to duration of anti-TNF therapy
is illustrated in Figure 1. Etanercept-associated TB cases were
distributed uniformly during the reporting period. In contrast,
43% of infliximab-associated cases occurred during the first
90 days of treatment, indicating they likely represent
reactivation of latent infection. The rate of tuberculosis
during the first 90 days of infliximab therapy was 95/
100,000 person-years, compared to 11/100,000 with etaner-
cept, and 5/100,000 in the US as a whole (CDC, 2001). The
TB rate associated with infliximab use declined progressively
during each successive 90-day interval, becoming equal to
that of etanercept after 1 year. The clustering of TB cases
shortly after initiation of anti-TNF therapy is consistent with
an etiology of reactivation.
Analyses of data from voluntary reporting systems such as
AERS may be compromised by incomplete reporting of
comorbid conditions, concomitant medications, and other
factors that may affect TB risk. However, Brassard et al.
(2006) recently reported similar findings following analysis of
TB risk in patients with rheumatoid arthritis using a large
Canadian insurance claims database. After controlling for
comorbid conditions, age, and sex, infliximab use in the
preceding year was associated with an adjusted rate ratio of
tuberculosis of 1.6 (95% CI, 1.0–2.6) whereas that for
etanercept was 1.2 (0.9–1.8). Brassard et al. (2006) also
found the median time to TB onset earlier with infliximab
(17 weeks, vs 79 for etanercept). These two studies appear to
indicate that only infliximab efficiently reactivates latent TB
infection.
TNF BLOCKADE AND HUMAN MYCOBACTERIAL
IMMUNITY IN VITRO
To better understand the immunologic basis of this differ-
ence, we recently reported a series of experiments using in
vitro conditions that mimic those in vivo during therapeutic
TNF blockade (Saliu et al., 2006). Experiments were
conducted using whole blood cultures of healthy, tuberculin
skin test reactive volunteers. Trough and peak drug concen-
trations of TNF blockers were added to the cultures, to reflect
those during treatment. M. tuberculosis culture filtrate was
selected as a stimulus for the cell cultures, based on its ability
to stimulate TNF expression in monocytes and both TNF and
IFN-g expression in T cells (Wallis et al., 1993). Cultures were
performed with fresh autologous plasma to permit comple-
ment activation by TNF–mAb immune complexes. Whole
blood culture (heparinized blood diluted with culture
medium) was used to permit expression of antibody-
dependent cell-mediated cytotoxicity in mixed cell popula-
tions. To our knowledge, no other published studies of the
mechanism of action of TNF blockers have adopted this
approach. The goal was to elucidate the mechanisms
underlying the differential tuberculosis risk of TNF blockers.
Effects on T-cell function
T-cell activation was assessed as CD69 expression, a marker
that is absent from resting cells and that is expressed soon
after antigen or mitogen stimulation. The median frequency
of TB culture filtrate-reactive CD4 T cells in the blood of the
tuberculin-reactive donors recruited for this study was 0.73%;
this was reduced to 0.37% by adalimumab and 0.22% by
infliximab (both Po0.05 by repeated measures analysis of
variance, the multiple test equivalent of the paired t-test)
(Saliu et al., 2006). In contrast, etanercept had no significant
effect, with a median frequency of 0.60%. Similar effects
were observed on responses to the mitogenic stimulus
phytohemagglutinin A.
The effects of TNF blockade on TB-induced production of
IFN-g are shown in Figure 2. Median baseline IFNg
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Figure 1. Cumulative proportion of TB cases in relation to start of anti-TNF
treatment. Each symbol represents a case reported to the US Food and Drug
Administration Adverse Event Reporting System between January 1998 and
March 2003. The two curves differed significantly by Kaplan–Meier analysis
(P¼0.00028). Adapted with permission from Wallis et al. (2004).
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production was 1,082 pg/ml (interquartile range, 651–1621).
Infliximab and adalimumab suppressed IFN-g production to
30% of baseline (Po0.05 by repeated-measures analysis of
variance) (Saliu et al., 2006). Significant effects of infliximab
were observed even at trough drug concentrations (5 mg/ml),
whether compared to control cultures without drug or to
corresponding cultures with etanercept. In contrast, etaner-
cept showed no statistically significant effect on IFNg
production compared to control cultures, even when tested
at a supratherapeutic concentration (5 mg/ml, equal to the
trough concentrations of the TNF mAbs).
We did not identify a mechanism for the inhibition of IFNg
production we observed. It was not due to T-cell death, either
by apoptosis or necrosis, as assessed by flow cytometry,
regardless of the stimulus (antigen or mitogen) or the selected
cell population (CD4 or CD8, all cells or only activated cells)
(Saliu et al., 2006). This implied that T-cell dysfunction,
rather than death, might account for our observations. We
considered IL-10 as a candidate mediator of this dysfunction,
as IL-10 production by monocytes is increased in patients
with tuberculosis, in whom it inhibits expression of IFNg and
costimulatory molecules (Shrikant et al., 1995; Hirsch et al.,
1999). IL-10 was produced in the TB-stimulated cultures,
with a median level of 875 pg/ml (interquartile range,
399–1,295). However, we observed that all three TNF
blockers equally inhibited TB-induced IL-10 production to
20–30% of baseline levels (all Po0.05 compared to control
by repeated measures analysis of variance) (Saliu et al.,
2006). This finding indicated that increased TB risk could not
be attributed to increased IL-10 production, and further, that
inhibition of IL-10 during TNF blockade appears not to
protect against reactivation of latent tuberculosis. Other
cytokines, such as transforming growth factor b and IFNa
have also been implicated in regulation of IFNg production in
tuberculosis (Hirsch et al., 1996; Manca et al., 2001). Further
studies will be required to determine the role of these
cytokines in the regulation of IFNg production by TNF mAbs.
Effects on intracellular mycobacterial survival
The whole blood intracellular infection model has been
advocated as a tool to study the host–pathogen interaction in
tuberculosis and the modulation of this interaction by
vaccination or immunosuppression (Kampmann et al.,
2000, 2004; Cheon et al., 2002; Hoft et al., 2002; Tena
et al., 2003). Mycobacteria added to whole blood cultures
rapidly undergo phagocytosis and are subject to cellular
immune mechanisms for control of growth of intracellular
pathogens. We used this model to examine the effects of TNF
blockade on the intracellular survival of M. tuberculosis
H37Ra, an attenuated strain whose viability typically
declines by 70% during the first 24-hour of whole blood
culture, and does not change subsequently (Janulionis et al.,
2005). Adalimumab and etanercept had divergent, concen-
tration-dependent effects on intracellular mycobacterial
viability during the first 24 hours (Figure 3), approaching
statistical significance at peak drug levels (P¼0.05 by
repeated-measures analysis of variance) (Saliu et al., 2006).
Mycobacterial viability was not further affected by TNF
blockade turning the subsequent 72 hours. Host effector
mechanisms expressed during the first 24 hours of whole
blood culture may include innate bactericidal mechanisms of
phagocytic cells, cellular cytotoxicity, and release of
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Figure 2. Effects of TNF blockade on antigen-induced production of IFNc in
whole blood cultures stimulated with M. tuberculosis culture filtrate.
Symbols represent median and interquartile range of 15 subjects. Median
IFNg without TNF blockers was 1,028 pg/ml. Asterisks indicate statistical
significance compared to untreated control cultures by repeated-measures
analysis of variance on ranks followed by post hoc testing using Dunn’s
method. Both trough and peak concentrations of adalimumab and infliximab
inhibited IFNg production, whereas etanercept did not, even at a
supratherapeutic concentration. Adapted with permission from Saliu et al.
(2006).
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Figure 3. Effects of TNF blockade on control of intracellular survival and
replication of M. tuberculosis during the first 24 hours of whole blood
culture. Values greater than 100% indicate mycobacterial growth, whereas
lower values indicate killing. Symbols indicate median and interquartile range
of 20 subjects. Divergent effects at peak levels approached statistical
significance at 24 hours (P¼0.05 by repeated measures analysis of variance),
although none of the treatments differed significantly from untreated controls.
Note: Overlapping error bars do not preclude differences by paired or
repeated measures testing. Adapted with permission from Saliu et al. (2006).
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antibacterial peptides. Additional studies will be required to
identify which of these mechanisms are differentially affected
by TNF blockade.
Effects on monocyte apoptosis
Lastly, we assessed the effects of TNF blockade on apoptosis
in TB-activated monocyte monolayers, by measurement of
histone-associated cytoplasmic DNA. This method permits
the analysis of apoptosis without requiring the removal of cell
monolayers by mechanical scraping or enzymatic digestion
(Salgame et al., 1997). It also avoids monocyte loss due to
adherence or clumping in activated mixed cell suspensions.
No significant effects were observed in 24-hour cultures
(Saliu et al., 2006). At 48 hours, peak concentrations of
infliximab resulted in a 40% increase in histone-associated
DNA compared to TB-stimulated control cultures, whereas
neither etanercept nor adalimumab caused a significant effect
(Po0.05 compared to control, Figure 4) (Saliu et al., 2006).
However, the biological significance of this observation is
uncertain, as other apoptotic stimuli (e.g., serum starvation)
produce up to 10-fold greater effects using this method
(Salgame et al., 1997). No effect was observed on monocyte
necrosis, assessed as Trypan blue permeability (Saliu et al.,
2006).
DISCUSSION
These data indicate that infliximab and etanercept differ
substantially with regard to granulomatous infection risk,
particularly reactivation of latent M. tuberculosis infection,
despite sharing TNF as a common therapeutic target. This is
accompanied by differential effects of these drugs on T-cell
activation and production of IFNg. IFNg, like TNF, is essential
for protection against M. tuberculosis challenge in animal
models (Flynn et al., 1993), owing to the capacity of IFNg to
activate macrophages and promote production of nitric oxide
(Kamijo et al., 1995). Children lacking the IFNg receptor have
markedly impaired anti-mycobacterial defenses, often deve-
loping disseminated disease following vaccination against
tuberculosis with the attenuated M. bovis strain Bacillus
Calmette Guerin (Jouanguy et al., 1996). In HIV/AIDS, CD4 T
cell loss both profoundly increases TB risk (Badri et al., 2002)
and markedly reduces antigen-induced IFNg production
(Wallis et al., 1998; Mayanja-Kizza et al., 2001). The risk
of reactivation of latent M. tuberculosis infection posed by
infliximab may therefore reflect its ability both to block the
effects of TNF and to inhibit production of IFNg.
Several theories have been advanced to account for the
differential effects of infliximab and etanercept on cell-
mediated host defenses and infection risk. According to a
pharmacokinetic hypothesis, the unique effects of infliximab
are due to high peak blood concentrations, which may
exceed 80 mg/ml (St Clair et al., 2002). Blood levels of
etanercept, in contrast, range only from 1 to 2 mg/ml
throughout the dosing interval (Amgen and Wyeth Pharma-
ceuticals, 2005). However, we observed significant differ-
ences with regard to inhibition of IFNg production even when
these drugs were tested at equal concentrations, arguing
against this as a key factor for TB risk. Moreover, this
hypothesis would suggest that adalimumab, with blood levels
ranging from 5 to 10 mg/ml (Abbott Laboratories, 2005),
should share the low TB risk of etanercept. Although clinical
experience with adalimumab is limited, its TB risk appears
similar to infliximab (Schiff et al., 2006).
Although all three drugs are comprised of two TNF-
binding domains linked to human IgG1 constant regions (Fc),
they can also be distinguished by important structural
differences. Infliximab and adalimumab are monoclonal
antibodies with murine and human variable (Fv) regions,
respectively, that recognize both monomeric and trimeric
TNF. In contrast, TNF binding by etanercept is mediated by
two human p75 TNF receptors recognizing only trimeric
TNF. A single molecule of infliximab may bind two distinct
TNF molecules. In solution, this may result in the formation of
immune complexes, causing complement activation and cell
lysis. On the cell surface, antibody binding may result in the
crosslinking of membrane TNF, triggering apoptosis owing to
what has been termed ‘‘reverse signaling’’ (Ringheanu et al.,
2004; Mitoma et al., 2005). Induction of apoptosis has been
proposed as a therapeutic mechanism for infliximab in
Crohn’s disease, a granulomatous inflammatory condition
for which etanercept is ineffective (Sandborn et al., 2001;
Van den Brande et al., 2003; Di Sabatino et al., 2004). We
observed neither apoptosis nor necrosis owing to either
infliximab or adalimumab in the whole blood model,
indicating that the inhibition of IFNg may be an independent
contributor to TB risk owing to these drugs.
Alternatively, the critical characteristic of infliximab and
adalimumab may instead be that their high-affinity binding of
TNF is essentially irreversible. In contrast, active TNF may be
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Figure 4. Effect of TNF blockade on apoptosis in 48-hour cultures of
M. tuberculosis culture filtrate-stimulated monocytes. Symbols indicate
median and interquartile range of 20 subjects. Apoptosis was measured by
enzyme linked immunoassay of histone associated cytoplasmic DNA.
Apoptosis in cultures treated with peak therapeutic concentrations of
infliximab was significantly greater than in control cultures by repeated-
measures analysis of variance, but reached only one-tenth the level reported
in cultures with other pro-apoptotic stimuli (Salgame et al., 1997). Adapted
with permission from Saliu et al. (2006).
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released after binding to TNFR2, a low-affinity receptor
(Scallon et al., 2002; Nestorov, 2005). Infliximab and
adalimumab may therefore neutralize TNF more completely,
thus accounting for both increased TB risk and inhibition of
IFNg. Further studies to examine the mechanism of this effect
are warranted.
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